Anakinra vs IVIG for kids who don’t respond to first IVIG
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 3 months and under 18 years old
- Your child weighs at least 5 kilograms
- Your child has Kawasaki disease and still has fever after the first IVIG infusion
- A parent or legal guardian can sign informed consent
- Your child has health insurance (French system: SS or CMU)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether anakinra is at least as effective as standard treatment for children with Kawasaki disease. It aims to prevent heart complications caused by inflammation in the blood vessels.
This trial tests adding a new drug, firsekibart, to standard immunoglobulin treatment for children with Kawasaki disease. The goal is to see if the combination is safe and works better than immunoglobulin alone.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
This study tests the best dose of a blood thinner called rivaroxaban for children with a giant coronary artery aneurysm after Kawasaki disease. The goal is to prevent dangerous blood clots.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.